Research programme: STAT4 inhibitors - AmgenAlternative Names: Interleukin-12 inhibitors research programme - Amgen; Research programme: interleukin-12 inhibitors - Amgen; STAT4 inhibitors research programme - Amgen
Latest Information Update: 27 Dec 2007
At a glance
- Originator Tularik
- Mechanism of Action Interleukin 12 inhibitors; STAT4 transcription factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 10 Mar 1999 Preclinical development for Immunological disorders in USA (Unknown route)